Isomorphic Labs closed an oversubscribed $5 billion Series C to scale its AI drug-design engine and expand a pipeline aimed at clinical entry, after a $1.2 billion Series B only six months earlier. In parallel, Merck and Isomorphic Labs announced a research collaboration to discover small-molecule oncology candidates for an undisclosed “strategic importance” target. Merck will own preclinical and clinical development, manufacturing, and commercialization, while Isomorphic contributes its simulation engine and Merck’s existing wet-lab data. Together, the funding and the Merck deal highlight how AI platforms are being operationalized through capital scale and pharma partnerships, with near-term emphasis on moving from preclinical claims to measurable translational outcomes.
Get the Daily Brief